Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
14 shown of 6,469 total abstracts
  1. Abstract LBA4000LBA2026-06-02 · 14:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-68
    F. Andre, S. Modi, H. Rugo · Royal Marsden Hospital
    Plenary SessionLung Cancer—Small Cell📄🖼️
  2. Abstract LBA4001LBA2026-06-05 · 15:00 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    N. Rizvi, P. Schmid, S. Modi · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract LBA4002LBA2026-06-02 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-275 study)
    M.C. Garassino, S. Modi · University of Chicago
    Plenary SessionLung Cancer—Small Cell📄🖼️
  4. Abstract LBA4003LBA2026-06-01 · 18:30 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    L. Paz-Ares, C. Robert, S. Tolaney · Karolinska Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract LBA4004LBA2026-06-03 · 18:00 CT · Arie Crown Theater
    IMpower-260: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    S. Antonia, P. Schmid, M. Krop, et al. · Karolinska Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract LBA4005LBA2026-06-04 · 20:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-406
    R. Herbst, J. Cortes, J. Brahmer · Institut Gustave Roussy
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract LBA4006LBA2026-06-03 · 14:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-953 study)
    S. Modi, N. Rizvi · University of Chicago
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract LBA4007LBA2026-06-03 · 21:00 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-411
    S. Peters, H. Borghaei, L. Paz-Ares, et al. · Massachusetts General Hospital
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract LBA4008LBA2026-06-04 · 16:15 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with NSCLC
    E. Winer, T. Mok, H. Rugo · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract LBA4009LBA2026-06-04 · 15:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-491
    L. Paz-Ares, H. Rugo, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract LBA4010LBA2026-06-05 · 18:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-518 study)
    E. Winer, T. Mok, J. Brahmer, et al. · University of Chicago
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract LBA4011LBA2026-06-03 · 16:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-761 study)
    P. Schmid, J. Brahmer, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract LBA4012LBA2026-06-05 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    C. Saura, N. Rizvi · Karolinska Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract LBA4013LBA2026-06-02 · 20:45 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-126
    J. Brahmer, S. Tolaney, H. Rugo, et al. · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.